"The Board of Directors of BioStem Technologies has accepted Henry’s decision to step down as CEO and chairman to focus on business development and sales,” said Matuszewski. “As one of the founders of BioStem Technologies, I have a profound commitment to the success of our company and to ensure the continual focus of our vision and the execution of our strategy. I am fully invested in reassuming the role of CEO until such a time that this important responsibility can be transitioned to the right person following a systematic search that will allow us to maintain our focus on our important fourth quarter.”
The company also announced the expansion of its leadership team with the addition of Ken Warrington, Ph.D., as senior vice president of Operations. Dr. Warrington brings significant expertise in biopharmaceutical product development and cGMP production. Dr. Warrington will play a key role in the expansion of the laboratory production and development initatives as BioStem continues to accelerate its growth of the BioStem Life Sciences division.
BioStem Technologies Inc. is a global life sciences corporation, providing technologies with a concentration in regenerative medicine. The company’s mission is to discover, develop and produce the most effective regenerative medicine products in the world. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create products. These technologies improve the quality of life for patients and, as a result, drive shareholder value.
BioStem Life Sciences Inc. is a company that develops birth tissue products for multiple sectors of healthcare. BioStem Life Sciences offers a comprehensive portfolio of brands that include Rheo, Vendaje, and Vendaje Optic. BioStem Life Sciences also provides contract manfuactuing services to GMP and GTP standards for companies looking to develop birth tissue products, from bench top to comericalization.